Satisfaction and quality of life of allergic patients following sublingual five-grass pollen tablet immunotherapy in Spain

Darío Antolín-Amerigo, Isabel A Tabar, Maria del Mar Fernández-Nieto, Anna M Callejo-Melgosa, Francisco J Muñoz-Bellido, José C Martínez-Alonso, Jorge D Méndez-Alcalde, Marta Reche, Ana Rodríguez-Trabado, Ana Rosado-Ingelmo, Alicia Alonso-Gómez, Rosa Blanco-González, José A Alvarez-Fernandez, Isabel Botella, Ana Valls, Mercedes Cimarra, Carlos Blanco

Article Type

Original Research

Published

This trial sought to determine the satisfaction and health-related quality of life (HRQoL) of patients undergoing five-grass pollen tablet treatment.

Read more

Bilastine in allergic rhinoconjunctivitis and urticaria: a practical approach to treatment decisions based on queries received by the medical information department

Amalia Leceta, Ander Sologuren, Román Valiente, Cristina Campo, Luis Labeaga

Article Type

Review

Published

Overall, this analysis highlights gaps in our knowledge regarding the optimal use of bilastine. Expert opinion based upon an understanding of the science can help in the decision-making, but more research is needed to provide evidence-based answers in certain circumstances.

Read more

Clinical factors, including All Patient Refined Diagnosis Related Group severity, as predictors of early rehospitalization after COPD exacerbation

Melissa H Roberts, Douglas W Mapel, Ann Von Worley, Janice Beene

Article Type

Original Research

Published

Patients hospitalized for chronic obstructive pulmonary disease (COPD) exacerbations carry a high risk for early rehospitalization. This study demonstrates that hospitals can use commonly collected clinical information to help identify COPD patients at a high risk of failure after discharge.

Read more

Safety and pharmacokinetics of extended use of palivizumab in Saudi Arabian infants and children

Saleh al-Alaiyan, Paul Pollack, Gerard F Notario

Article Type

Case Report

Published

The peak season of respiratory syncytial virus (RSV) infections in warmer climates may extend beyond the typical five-month RSV season of temperate regions. This study aimed to assess the safety, immunogenicity, and pharmacokinetics of an extended seven-dose regimen of palivizumab in children at high risk for serious infection by the RSV.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.